Avoiding Anticoagulation After IntraCerebral Haemorrhage

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT03243175

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03243175
  • EudraCT 2017-004371-31
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03243175. Randomized; single masking; primary purpose prevention. Start 2019-01-17 (actual); primary completion 2029-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Avoiding Anticoagulation After IntraCerebral Haemorrhage
Acronym
A3ICH
Condition
Intracerebral Hemorrhage
Condition
Microhaemorrhage
Intervention (Drug)
Apixaban 5 MG
Intervention (Device)
left atrial appendage closure
Lead sponsor
University Hospital, Lille (class: other)
Collaborator
Ministry of Health, France (class: other government)
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (class: other government)

Record details

Record id
cardio:ct-nct03243175
Content hash
d99eda65a8494ac01b7baa1c1478348c9b717839d3057ec6f159951a60f67520